Test Price
1,200 AED✅ Home Collection Available
BCR-ABL Variant Panel (Mbcr-b2a2, b3a2, b2a3) – 1,200 AED – Molecular Oncology Test in Dubai
Executive Summary & Core Metrics
Executive Summary & Compliance
Accuracy Guarantee: 99.9% diagnostic sensitivity for major BCR-ABL breakpoint transcripts (b2a2, b3a2, b2a3) via multiplex endpoint PCR in an ISO 9001:2015 certified facility.
Clinical Relevance: Essential for diagnosing and monitoring chronic myeloid leukemia (CML) and Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL). Guides tyrosine kinase inhibitor selection and treatment response.
Collection Protocol: Hospital Extraction Only – sample collection (bone marrow or peripheral blood) is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Insurance Support: Direct billing verification – send your Emirates ID and policy via WhatsApp to +971 54 548 8731.
Test Overview & Methodology
The BCR-ABL Variant Panel uses multiplex endpoint PCR to specifically detect the three major breakpoint cluster region transcripts (b2a2, b3a2, b2a3) that encode the p210 fusion protein. This molecular assay surpasses standard quantitative PCR by resolving individual splice variants, enabling precise risk stratification and tailored therapy according to European LeukemiaNet (ELN) guidelines.
| Feature | Our BCR-ABL Variant Panel | Standard BCR-ABL qPCR |
|---|---|---|
| Detection Method | Multiplex End Point PCR – identifies individual variants (b2a2, b3a2, b2a3) | Quantitative real‑time PCR – total BCR-ABL (often p210 only) |
| Clinical Specificity | High – distinct transcript sub‑types for tailored therapy | Moderate – does not resolve individual splice variants |
| Turnaround Time | 5–7 working days | 7–10 working days |
| Price | 1,200 AED | ~950–1,100 AED (variable) |
Resolving individual transcripts enables ELN‑guided management, including early prognostic assessment and therapy selection.
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor (Specialist Diagnostic Radiology, DHA Registration ID: 61713011): “Molecular findings from this panel must be correlated with complete blood counts, bone marrow aspirate, and clinical symptoms. Never interpret a result in isolation – a haematologist’s evaluation is essential for therapeutic decisions.”
Advisory: Medication Vigilance
⚠️ Important Medication Warning:
Do not discontinue or adjust prescribed tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, etc.) without consulting your treating oncologist. Altering therapy based solely on a single PCR result can lead to disease progression.
Exclusion & Emergency Red Flags
🚨 Patient Safety Exclusion & Emergency Red Flags
- Exclusion Criteria: Patients with active severe infection (sepsis, febrile neutropenia) or hemodynamic instability should postpone elective bone marrow collection until clinically stable.
- Immediate Medical Attention Required If: You develop sudden high fever (>38.5 °C), uncontrolled bleeding/bruising, severe bone pain, or visual disturbances – these may indicate leukostasis or blast crisis.
- Bone Marrow Procedure: Only performed by a licensed healthcare professional; local anaesthesia is used, but inform the team of any bleeding disorders or anticoagulant use.
Patient FAQ & Clinical Guidance
1. What specific variants does the BCR-ABL panel detect?
This panel accurately identifies major breakpoint cluster region transcripts b2a2, b3a2, and b2a3 (p210), which are essential molecular markers for chronic myeloid leukemia and Ph+ ALL.
2. Is a doctor’s prescription mandatory for this test in the UAE?
Yes, a valid prescription from a DHA‑licensed physician is compulsory, except for pre‑surgical clearance, pregnancy‑related screening, or international travel documentation as per DHA circulars.
3. How should I prepare for the BCR-ABL sample collection?
No fasting is required; simply inform the phlebotomist of any anticoagulant medications. Bone marrow draws are performed under strict aseptic conditions by a specialist. If peripheral blood is collected, standard venipuncture is used.
UAE Regulatory & Data Privacy Adherence
🔒 Trust & Compliance Framework
Your health data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
All testing procedures are performed at DNA Labs UAE, a DHA‑licensed laboratory (License No. 1143) operating under ISO 9001:2015 quality management.
Clinical & Logistical Metadata
| Test Name | BCR-ABL Variant Panel (Mbcr-b2a2, b3a2, b2a3) |
| Price (AED) | 1,200 AED |
| Turnaround Time | 5–7 working days |
| Sample Type / Matrix | Bone Marrow / Peripheral Blood – Hospital Extraction Only |
| Methodology Used | Multiplex End Point PCR |
| ICD-10-CM Code | C92.1 (Chronic myeloid leukemia, BCR/ABL-positive) |
| LOINC Code | 33754-4 (BCR-ABL major breakpoint [Presence] in Blood or Bone marrow by PCR) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians